Dynamin-like 120 kDa mitochondrial GTPase (OPA1) (OPA1)

Dynamin-like 120 kDa mitochondrial GTPase (OPA1) is a nuclear-encoded protein localized to the inner mitochondrial membrane, where it serves as a master regulator of mitochondrial morphology and energetics (UniProt: P58281). It is essential for the fusion of the inner mitochondrial membrane, the maintenance of cristae integrity, and the protection of cells against apoptosis by sequestering cytochrome c (PMID: 30639420). Mutations in the OPA1 gene are the leading cause of Autosomal Dominant Optic Atrophy (ADOA), a hereditary optic neuropathy resulting from the selective degeneration of retinal ganglion cells (OMIM: 605290). Beyond vision loss, OPA1 dysfunction is linked to "OPA1-plus" syndromes involving deafness, ataxia, and myopathy, as well as broader neurodegenerative processes (PMID: 26076067). Current therapeutic development focuses on gene-based approaches, such as antisense oligonucleotides and AAV-mediated gene replacement, to restore sufficient OPA1 protein levels in haploinsufficient patients (PYC Therapeutics, 2023). Small molecule research also explores the stabilization of mitochondrial dynamics to mitigate the effects of OPA1 deficiency. As a critical component of mitochondrial health, OPA1 represents a promising target for addressing both rare genetic disorders and more common age-related neurodegenerative conditions.

Other names

Optic atrophy 1MGM1KIAA0453NPGNTGBERHS

Gene replacement therapy to restore OPA1 expression; antisense oligonucleotides to increase protein production from the wild-type allele; small molecules to stabilize mitochondrial fusion.